Skip to main content
Synbiotic SE logo

Synbiotic SE — Investor Relations & Filings

Ticker · SBX ISIN · DE000A3E5A59 LEI · 48510041U2G1IWA3R418 F Manufacturing
Open in API
Filings indexed 140 across all filing types
Latest filing 2021-10-27 Share Issue/Capital Cha…
Country DE Germany
Listing F SBX

About Synbiotic SE

https://www.synbiotic.com/

Synbiotic SE is a European corporate group focused on the medical cannabis and industrial hemp markets. The company operates a platform model, making strategic investments in ventures across these sectors to create synergies. Its business is vertically integrated, covering the entire value chain from cultivation, research, and development to the production, sales, and distribution of hemp- and cannabinoid-based products. The company's portfolio includes a wide range of high-quality hemp, CBD, and cannabis products, leveraging its expertise across the full supply chain from seed to shelf.

Recent filings

Filing Released Lang Actions
Another seven million Euros for SynBiotic SE
Share Issue/Capital Change Classification · 99% confidence The document is a news release announcing that SynBiotic SE has successfully completed a capital increase, placing 334,000 new shares to raise approximately 7 million Euros. The key phrase indicating the nature of the filing is 'Key word(s): Capital Increase'. This directly relates to fundraising and capital structure changes. Based on the definitions, 'Capital/Financing Update' (Code: CAP) is the most appropriate classification for an announcement detailing the successful placement of new shares for growth financing.
2021-10-27 English
SynBiotic SE plans Canadian cross-listing
Regulatory Filings Classification · 95% confidence The document is a 'Media' release dated October 12, 2021, announcing that SynBiotic SE plans a cross-listing on the Canadian NEO Exchange. It discusses strategic reasons for accessing capital and gaining visibility in the cannabis sector. The text is clearly a press release disseminated via DGAP, which handles 'Regulatory Announcements, Financial/Corporate News and Press Releases.' Since the content is a strategic announcement about future financing/market access rather than a specific financial report (like 10-K, IR, ER) or a transaction report (like DIRS, POS), it fits best under the general regulatory/news announcement category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate news announcement that doesn't fit a more specific category like Capital/Financing Update (CAP) or Delisting (DLST). While it relates to capital markets, it is an announcement *about* a listing plan, not the execution of financing or a formal filing of results. RNS serves as the best general regulatory news category here.
2021-10-12 English
SynBiotic SE: Plant kanadisches Zweitlisting
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad-hoc' announcement dated October 7, 2021, published via DGAP, which explicitly states it is an 'Insiderinformation gem. Artikel 17 MAR' (Insider Information pursuant to Article 17 MAR). The core content announces that SynBiotic SE is planning a secondary listing on the Canadian NEO Exchange. This type of announcement, detailing a significant corporate action (a planned capital market event/listing) released immediately under regulatory disclosure rules (MAR Article 17), fits best under the category of Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Since the primary subject is a planned listing/financing activity, CAP is more specific than RNS. It is not a full report (10-K, IR), a transcript (CT), or a management discussion (MDA). Given the nature of planning a listing, CAP is the most appropriate classification.
2021-10-07 German
DGAP-DD: SynBiotic SE deutsch
Director's Dealing Classification · 100% confidence The document is titled 'DGAP-DD: SynBiotic SE deutsch' and contains the header 'Directors’ Dealings'. Section 1 identifies the person involved (Lars Müller) and Section 2 confirms their position as 'Geschäftsführender Direktor' (Managing Director). Section 4 details a transaction ('Gewährung von 480.000 Bezugsrechten'). This content directly corresponds to the definition of Director's Dealing, which is classified as 'DIRS'. The document is a specific regulatory disclosure about insider transactions, not a general announcement of a report (RPA) or a broad regulatory filing (RNS).
2021-10-06 German
DGAP-DD: SynBiotic SE deutsch
Director's Dealing Classification · 100% confidence The document is titled 'DGAP-DD: SynBiotic SE deutsch' and contains the header 'Directors’ Dealings'. The content explicitly details transactions ('Geschäfte') involving a person closely related to management ('Person steht in enger Beziehung zu: Lars Müller, Geschäftsführender Direktor'). This directly corresponds to the definition of Director's Dealing reports, which track personal share transactions by directors and executives. The appropriate code is DIRS.
2021-10-06 German
DGAP-DD: SynBiotic SE deutsch
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains the German equivalent header 'DGAP-DD: Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen'. This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The content details a transaction involving a member of the Supervisory Board ('Aufsichtsrat'). Therefore, the correct classification is DIRS.
2021-10-06 German

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.